Marinus Pharmaceuticals (NASDAQ:MRNS) Lifted to Outperform at Oppenheimer

Oppenheimer upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a market perform rating to an outperform rating in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The firm currently has $6.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald reiterated an overweight rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Monday, September 16th. StockNews.com upgraded shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, September 18th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a buy rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, Truist Financial reiterated a buy rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $8.83.

Marinus Pharmaceuticals Stock Down 8.4 %

Marinus Pharmaceuticals stock opened at $1.74 on Monday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. The stock has a market cap of $95.84 million, a PE ratio of -0.66 and a beta of 1.13. Marinus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $11.26. The firm’s 50-day simple moving average is $1.40 and its 200 day simple moving average is $2.67.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter in the previous year, the firm earned ($0.61) EPS. Research analysts predict that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $34,000. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $64,000. Finally, Values First Advisors Inc. grew its position in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.